Merck and Portola’s Agreement on Anticoagulant Drug
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 7 (Table of Contents)
Published: 15 Jul-2009
DOI: 10.3833/pdr.v2009.i7.1135 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In another deal to strengthen its cardiovascular franchise, Merck & Co has signed an exclusive deal to develop and market Portola Pharmaceuticals’ betrixaban, a Factor Xa inhibitor...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS